Sanofi Consumer Healthcare India Limited has informed the Exchange about Investor Presentation
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanofi Consumer Healthcare India shared its investor presentation for an institutional investor meet held on 24 March 2026, themed 'Re-igniting Profitable Growth.' For FY25, the company reported revenue from operations of ₹8,784 Mn with a strong profit margin of 36.7% and ROCE of 62.5%. Growth versus FY24 was robust: revenue up 21%, operating profit up 13%, and profit after tax up 33%. The strategy focuses on scaling doctor reach (2x), consumer engagement (~60 Mn multimedia reach), and direct retail coverage (2x) under a vision to become the best Fast Moving Consumer Healthcare (FMCH) company in India. The presentation provides context on its 2024 demerger from Sanofi India, post-recall recovery, brand re-launches (DePURA 60K, Combiflam and Allegra suspensions, DePURA Kids), and global benefits from parent Opella's scale.
Positive for shareholders — the company is showing strong profitable growth and margin profile, with a clear FMCH-led strategy. However, the company acknowledges it has been significantly underinvesting versus peers in media, HCP coverage, and direct store reach, so planned step-ups in spending could pressure short-term margins even as revenue scales.